Novel pharmaceutical compositions for modulating angiogenesis

Pharmaceutical composition for modulating angiogenesis comprising a therapeutically effective amount of an angiogenesis modulating compound and a pharmaceutically acceptable excipient, wherein said modulating compound is a recombinant caveolin-1 or a pharmacologically acceptable derivative thereof.

Pharmaceutical composition for modulating angiogenesis comprising a therapeutically effective amount of an angiogenesis modulating compound and a pharmaceutically acceptable excipient, wherein said modulating compound is a nucleic acid encoding the partial or total amino acid sequence of caveolin-1, or an analogue thereof.

Pharmaceutical composition for modulating angiogenesis comprising a therapeutically effective amount of an angiogenesis modulating compound and a pharmaceutically acceptable excipient, wherein said modulating compound is a nucleic acid modulating the expression of caveolin-1 thereby interfering with promoter, silencer or activator molecules or cites influencing the caveolin-1 mRNA population.

Pharmaceutical composition for modulating angiogenesis comprising a therapeutically effective amount of an angiogenesis modulating compound and a pharmaceutically acceptable excipient, wherein said modulating compound is influencing the translation or stability of the caveolin-1 mRNA.

Pharmaceutical composition for modulating angiogenesis comprising a therapeutically effective amount of an angiogenesis modulating compound and a pharmaceutically acceptable excipient, wherein said modulating compound is a agonist or an antagonist of caveolin-1 thereby influencing the caveolin-1 activity.

Pharmaceutical composition for modulating angiogenesis comprising a therapeutically effective amount of an angiogenesis modulating compound and a pharmaceutically acceptable excipient, wherein said modulating compound is a competitive inhibitor of caveolin-1 by inhibiting the binding of the binding partners.

Pharmaceutical composition for modulating angiogenesis comprising a therapeutically effective amount of an angiogenesis modulating compound and a pharmaceutically acceptable excipient, wherein said modulating compound is a recombinant hsp90, a nucleic acid encoding the partial or total amino acid sequence of hsp90 or a pharmacologically acceptable derivative thereof or an analogue thereof.

Pharmaceutical composition for modulating angiogenesis comprising a therapeutically effective amount of an angiogenesis modulating compound and a pharmaceutically acceptable excipient, wherein said modulating compound is a recombinant hsp90, or a pharmacologically acceptable derivative thereof.

Pharmaceutical composition for modulating angiogenesis comprising a therapeutically effective amount of an angiogenesis modulating compound and a pharmaceutically acceptable excipient, wherein said modulating compound is a nucleic acid encoding the partial or total amino acid sequence of hsp90 or an analogue thereof.

Pharmaceutical composition for modulating angiogenesis comprising a therapeutically effective amount of an angiogenesis modulating compound and a pharmaceutically acceptable excipient, wherein said modulating compound is a nucleic acid modulating the expression of hsp90 thereby interfering with promoter/silencer/activator molecules/cites influencing the hsp90 mRNA population.

Pharmaceutical composition for modulating angiogenesis comprising a therapeutically effective amount of an angiogenesis modulating compound and a pharmaceutically acceptable excipient, wherein said modulating compound is influencing the translation or stability of the hsp90 mRNA.

Pharmaceutical composition for modulating angiogenesis comprising a therapeutically effective amount of an angiogenesis modulating compound and a pharmaceutically acceptable excipient, wherein said modulating compound is a agonist or an antagonist of hsp90 thereby influencing the hsp90 activity.

Pharmaceutical composition for modulating angiogenesis comprising a therapeutically effective amount of an angiogenesis modulating compound and a pharmaceutically acceptable excipient, wherein said modulating compound is a competitive inhibitor of hsp90 by inhibiting the binding of the binding partners.

Pharmaceutical composition for modulating angiogenesis comprising a therapeutically effective amount of an angiogenesis modulating compound and a pharmaceutically acceptable excipient, wherein said modulating compound is a recombinant Akt, a nucleic acid encoding the partial or total amino acid sequence of Akt or a pharmacologically acceptable derivative thereof or an analogue thereof.

Pharmaceutical composition for modulating angiogenesis comprising a therapeutically effective amount of an angiogenesis modulating compound and a pharmaceutically acceptable excipient, wherein said modulating compound is a recombinant Akt, or a pharmacologically acceptable derivative thereof.

Pharmaceutical composition for modulating angiogenesis comprising a therapeutically effective amount of an angiogenesis modulating compound and a pharmaceutically acceptable excipient, wherein said modulating compound is a nucleic acid encoding the partial or total amino acid sequence of Akt or an analogue thereof.

Pharmaceutical composition for modulating angiogenesis comprising a therapeutically effective amount of an angiogenesis modulating compound and a pharmaceutically acceptable excipient, wherein said modulating compound is a nucleic acid modulating the expression of Akt thereby interfering with promoter, silencer or activator molecules or cites influencing the Akt mRNA population.

Pharmaceutical composition for modulating angiogenesis comprising a therapeutically effective amount of an angiogenesis modulating compound and a pharmaceutically acceptable excipient, wherein said modulating compound is influencing the translation or stability of the Akt mRNA.

Pharmaceutical composition for modulating angiogenesis comprising a therapeutically effective amount of an angiogenesis modulating compound and a pharmaceutically acceptable excipient, wherein said modulating compound is a agonist or an antagonist of Akt thereby influencing the Akt activity.

Pharmaceutical composition for modulating angiogenesis comprising a therapeutically effective amount of an angiogenesis modulating compound and a pharmaceutically acceptable excipient, wherein said modulating compound is a competitive inhibitor of Akt by inhibiting the binding of the binding partners.

A composition containing a statin and hsp90 and/or Akt or a pharmacologically acceptable derivative thereof as a combined preparation for simultaneous, separate or sequential use in a therapy in an angiogenesis-related disease.

A composition comprising a growth factor and hsp90 and/or Akt or a pharmacologically acceptable derivative thereof as a combined preparation for simultaneous, separate or sequential use in a therapy in an angiogenesis-related disease.

Use of hsp90 and/or Akt, or a pharmacologically acceptable derivative thereof, for the manufacturing of a medicament for the modulation of proangiogenic actions of statins and/or growth factors.

Method of modulating angiogenesis comprising the step of trapping endogenous caveolin-1 by a trapping compound thereby preventing its binding to the endothelial isoform nitric oxide synthase (eNOS).

A method of modulating angiogenesis comprising the step of trapping endogenous eNOS by a trapping compound whereby said trapping compound is mimicks caveolin-1.

Method of modulating angiogenesis comprising the step of overexpressing or improving the activity of caveolin-1, hsp90, and/or Akt.

Method of modulating angiogenesis comprising the step of reducing the abundance and/or activity of caveolin-1, hsp90 and/or Akt.

A diagnostic kit for the testing of a compound or a composition for their ability to modulate angiogenesis comprising an angiogenesis modulating compound wherein said modulating compound is a recombinant of caveolin-1, a nucleic acid encoding the partial or total amino acid sequence of caveolin-1, or an analogue thereof or a pharmacologically acceptable derivative thereof, a compound modulating the expression of caveolin-1, an agonist or an antagonist or a competitive inhibitor of caveolin-1, a recombinant hsp90, a nucleic acid encoding the partial or total amino acid sequence of hsp90 or an analogue thereof or a pharmacologically acceptable derivative thereof, a compound modulating the expression of hsp90, an agonist or an antagonist or a competitive inhibitor of hsp90, a recombinant of Akt, a nucleic acid encoding the partial or total amino acid sequence of Akt, or an analogue thereof or a pharmacologically acceptable derivative thereof, a compound modulating the expression of Akt, an agonist or an antagonist or a competitive inhibitor of Akt

Method for the treatment of angiogenesis related diseases comprising the step of administering a therapeutically effective amount of an angiogenesis modulating compound to an individual in need thereof, wherein said modulating compound is a recombinant of caveolin-1, a nucleic acid encoding the partial or total amino acid sequence of caveolin-1, or an analogue thereof or a pharmacologically acceptable derivative thereof, a compound modulating the expression of caveolin-1, an agonist or an antagonist or a competitive inhibitor of caveolin-1, a recombinant hsp90, a nucleic acid encoding the partial or total amino acid sequence of hsp90 or an analogue thereof or a pharmacologically acceptable derivative thereof, a compound modulating the expression of hsp90, an agonist or an antagonist or a competitive inhibitor of hsp90, a recombinant of Akt, a nucleic acid encoding the partial or total amino acid sequence of Akt, or an analogue thereof or a pharmacologically acceptable derivative thereof, a compound modulating the expression of Akt, an agonist or an antagonist or a competitive inhibitor of Akt